Blood Screening Market: Market Size & Forecast 2026

Blood screening represents a critical component of transfusion medicine, involving the testing of donated blood units for pathogens such as HIV, hepatitis B and C, syphilis, and other infectious agents before clinical use. The market encompasses reagents, instruments, software, and services utilized in blood banks, hospitals, and diagnostic laboratories globally. Industry estimates place the 2025 market value between $3.24 billion and $4.2 billion across various commercial analyses, reflecting the sector's essential role in healthcare safety infrastructure.

• •Market encompasses reagents, instruments, and software for infectious disease testing and blood typing
• •Critical for ensuring transfusion safety in hospitals, blood banks, and clinical laboratories
• •Multiple independent estimates converge on 2025 values between $3.2 billion and $4.2 billion

The primary catalyst for market expansion is the increasing global volume of blood transfusions and donations, particularly in developing healthcare systems undergoing modernization. Rising prevalence of infectious diseases and aging populations requiring more frequent transfusions contribute to sustained demand. Additionally, regulatory mandates enforcing rigorous blood safety protocols across jurisdictions compel continuous investment in advanced screening technologies and replacement of outdated equipment.

• •Growing blood donation rates and transfusion volumes across both developed and emerging markets
• •Stringent government regulations mandating comprehensive infectious disease testing of all donated blood
• •Technological advancements enabling faster, more accurate detection of emerging pathogens

The market segments primarily by product type, including reagents and kits, instruments, and software and services, with reagents representing the largest revenue component due to recurring consumption. Technology categories encompass nucleic acid testing, ELISA, rapid tests, and western blot assays, each serving specific screening requirements. Geographically, North America currently leads market share due to established healthcare infrastructure and strict regulatory frameworks, while Asia-Pacific exhibits the fastest growth trajectory driven by expanding healthcare access and rising screening adoption.

• •Reagents and consumables dominate product revenue through repeat purchase cycles
• •Nucleic acid testing (NAT) represents the fastest-growing technology segment
• •Asia-Pacific emerging as highest-growth region while North America maintains largest absolute market share

What are the recent trends and outlook?

The market's future trajectory points toward continued expansion through 2030-2035, with consensus growth projections clustering around 9-12% annually across industry analyses. Key trends include adoption of multiplex testing platforms capable of simultaneous detection of multiple pathogens, integration of artificial intelligence for result interpretation, and miniaturization enabling point-of-care screening capabilities. The cumulative effect of these developments, combined with ongoing healthcare infrastructure investments in emerging economies, positions the sector for sustained long-term growth as blood safety standards continue to evolve globally.

• •Multiplex and high-throughput screening technologies gaining adoption to improve laboratory efficiency
• •Emerging markets driving volume growth as healthcare systems expand blood safety programs
• •Market projections extending through 2035 with total addressable market potentially reaching $6-11 billion depending on scope